Candida albicans is almost always susceptible to fluconazole. Candida glabrata is often susceptible to fluconazole but dose-dependent, whereby increased drug exposure above typically used doses can predict susceptibility. Candida lusitaniae is intrinsically resistant to amphotericin B. Candida krusei is intrinsically resistant to fluconazole but often susceptible to voriconazole and echinocandins. Fluconazole has activity against Cryptococcus neoformans.
National data from the Canadian Antimicrobial Resistance Alliance (CARA) has demonstrated a significant shift in the proportion of Candida glabrata bloodstream infections over time, increasing from 16.4% to 22.0% from 2011 to 2016, respectively, and a concomitant decrease in Candida albicans bloodstream infections from 60.9% to 42.1%.
Check out different strains of Candida spp. listed under ‘Pathogens’ to find out more about local antifungal resistance patterns in Saskatchewan.